SLC19A3 antibody (C-Term)

Catalog No. ABIN5516361

This Rabbit Polyclonal antibody specifically detects SLC19A3 in WB. It exhibits reactivity toward Human.

Quick Overview for SLC19A3 antibody (C-Term) (ABIN5516361)

Target: SLC19A3 (Slc19a3) (Solute Carrier Family 19, Member 3 (Slc19a3))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This SLC19A3 antibody is un-conjugated

Application: Western Blotting (WB)

Product Details anti-SLC19A3 Antibody

Binding Specificity: C-Term

Purpose: SLC19A3 Antibody - C-terminal region

Sequence: VYGSYFAVIA GIFLMRSMYI TYSTKSQKDV QSPAPSENPD VSHPEEESNI

Purification: Affinity purified

Immunogen: The immunogen is a synthetic peptide directed towards the C terminal region of human SLC19A3

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

We also sell a specific blocking peptide that can be used in combination with this antibody. You can find the blocking peptide under AAP74823-100UG

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.5 mg/mL

Buffer: Purified antibody supplied in 1x PBS buffer with 0.09 % (w/v) sodium azide and 2 % sucrose.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: prevent freeze-thaw cycles

Storage: 4 °C,-20 °C

Storage Comment: For short term use, store at 2-8C up to 1 week. For long term storage, store at -20 °C in small aliquots to prevent freeze-thaw cycles.

Target Details for SLC19A3

Target: SLC19A3 (Slc19a3) (Solute Carrier Family 19, Member 3 (Slc19a3))

Alternative Name: SLC19A3

Background:

Background Information: This gene encodes a ubiquitously expressed transmembrane thiamine transporter that lacks folate transport activity. Mutations in this gene cause biotin-responsive basal ganglia disease (BBGD); a recessive disorder manifested in childhood that progresses to chronic encephalopathy, dystonia, quadriparesis, and death if untreated. Patients with BBGD have bilateral necrosis in the head of the caudate nucleus and in the putamen. Administration of high doses of biotin in the early progression of the disorder eliminates pathological symptoms while delayed treatment results in residual paraparesis, mild mental retardation, or dystonia. Administration of thiamine is ineffective in the treatment of this disorder. Experiments have failed to show that this protein can transport biotin. Mutations in this gene also cause a Wernicke's-like encephalopathy.

Gene Name: solute carrier family 19 member 3

Alternative Symbols: BBGD, THMD2, THTR2, thTr-2

Protein Name: thiamine transporter 2

Molecular Weight: 55 kDa

Gene ID: 80704

NCBI Accession: NP_079519

UniProt: Q9BZV2

Pathways: Dicarboxylic Acid Transport